QTRX, US74766Q1013

Quanterix stock gets interim CEO as Cunningham steps down

Published on 11/19/2026 at 03:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Quanterix stock enters a leadership transition after Everett Cunningham left as CEO on November 18. Jim Gute becomes interim CEO as the company reaffirms its 2026 outlook.

Leadership change reshapes Quanterix outlook

  • Everett Cunningham left Quanterix as president and CEO and departed the company board effective November 18.
  • Chief Commercial Officer Jim Gute will serve as interim president and CEO while the board searches for a permanent successor.
  • Quanterix reaffirmed its 2026 financial outlook and highlighted diagnostics and commercial execution as priorities.
QTRX, US74766Q1013, Illustration mit AI erstellt.

Quanterix announced on Wednesday, November 18, that Everett Cunningham had stepped down as president and chief executive officer, effective immediately, and had also left the company board. In its leadership transition announcement, the company said Cunningham was leaving to accept another opportunity in the healthcare sector.

Interim leadership takes effect immediately

Quanterix appointed Chief Commercial Officer Jim Gute to the additional role of interim president and CEO. The board has begun a search for a permanent chief executive with support from an executive search firm and will consider internal and external candidates.

Cunningham will remain available to support an orderly handover through December 11. Gute joined Quanterix as chief commercial officer in August 2026 after senior commercial roles at Exact Sciences and GE Healthcare.

Focus remains on commercial execution

The company reaffirmed the financial outlook it provided on November 9. Management said the business will remain focused on improving commercial execution, accelerating revenue growth and expanding its diagnostics position, while the board described the company as having opportunities in Alzheimer disease testing and research tools.

For investors, the leadership change adds a management transition to Quanterix's existing execution agenda. The search for a permanent CEO and the company's ability to maintain its financial outlook are the next key developments to watch.

Precision biomarker technology business

Quanterix develops precision biomarker technologies for disease research, diagnostics and drug development. Its SIMOA platform measures biomarkers in blood and other fluids at very low concentrations, while its Spatial solutions provide high-plex protein analysis in tissue at single-cell resolution. The company also operates Accelerator Laboratory services and is based in Billerica, Massachusetts.

Quanterix at a glance

  • Company: Quanterix Corporation
  • ISIN: US74766Q1013
  • Ticker: QTRX
  • Headquarters: Billerica, Massachusetts, United States
  • Leadership event: Jim Gute appointed interim president and CEO effective November 18, 2026

The broader U.S. market backdrop is covered through the S&P 500 market environment.

For more news and analyses on Quanterix stock, follow the company topic page.

Disclaimer...
en | US74766Q1013 | QTRX | boerse | 70533349 | bgmi